Company / PP&E (Net)
Cogent Biosciences, Inc. PP&E (Net) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$5.5M
FY2025
5-year range
$1.7M / $8.3M
FY2021-FY2025
Trend
-15.6%
vs FY2024
Sector context
#110 of 195
Health Care
What the data says
At $5M, Cogent Biosciences, Inc.'s pp&e (net) ranks #110 of 195 in the Health Care sector. Declined from $8M to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of +109.9%.
Declined from $8M to $5M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -11.2%
- 5-Year CAGR
- +109.9%
- 10-Year CAGR
- -
Sector benchmark
#110 of 195 in Health CareTop 56% of 195This company $5.5M Sector average $771.3M
▼
-99.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +109.9%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 15.6% year-over-year.
- Ranks #110 out of 195 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.5M | -15.6% |
| FY2024 | $6.5M | -22.5% |
| FY2023 | $8.3M | +7.2% |
| FY2022 | $7.8M | +356.2% |
| FY2021 | $1.7M | +1173.1% |
| FY2020 | $134.0K | -92.8% |
| FY2019 | $1.9M | -42.6% |
| FY2018 | $3.3M | -20.9% |
| FY2017 | $4.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026